The Business Fame, in collaboration with Scriberlee, hosted the third edition of the Premier Technology & Innovation ...
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...
Apex Fintech Solutions Inc. ("Apex"), an innovation launchpad for the global investment ecosystem, has announced the release ...
Leading Chinese module manufacturer Trinasolar has developed an 808W solar module that uses perovskite/silicon tandem solar ...
Vertex at £850 million pounds per year would ... “We’ve all seen the finger pointing. Every link in the supply chain has gotten skilled at that. But, like most Americans, I’m sick and ...
Together with Lodestone Energy, Trinasolar is contributing to New Zealand's zero-carbon targets while setting global standards for agrivoltaics.
Cloud Editions 25.2 brings together a comprehensive set of enterprise capabilities for process automation, data, security and AI. OpenText CE 25.2 wi ...
Stockhead on MSN4d
Lunch Wrap: ASX battered as ‘Liberation Day’ looms; copper downgraded while gold hits recordsThe ASX fell heavily to start the week, down by 1.5% at lunch time AEDT following a big sell-off in the US on Friday.
AI4Beginners (English) on MSN4d
"Is Your Business Falling Behind? Naresh Erukulla Reveals How Real-Time BI is Changing the Game!"In today’s digital economy, businesses generate and process unprecedented amounts of data every second. However, acces ...
GlobalData on MSN4d
Vertex halts development of diabetes cell therapy after trial failureVertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback